{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:00:49Z","timestamp":1791806449116,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.ejps.2004.01.005","type":"journal-article","created":{"date-parts":[[2004,3,6]],"date-time":"2004-03-06T10:39:45Z","timestamp":1078569585000},"page":"645-653","source":"Crossref","is-referenced-by-count":172,"title":["Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study"],"prefix":"10.1016","volume":"21","author":[{"given":"D","family":"Wexler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Banfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Laughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2004.01.005_BIB1","first-page":"63","article-title":"Voriconazole","volume":"44","author":"Abramowicz","year":"2002","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.ejps.2004.01.005_BIB2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1517\/14728214.5.2.135","article-title":"New agents for treatment of systemic fungal infections","volume":"5","author":"Arikan","year":"2000","journal-title":"Emerg. Drugs"},{"key":"10.1016\/j.ejps.2004.01.005_BIB3","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/AAC.44.10.2604-2608.2000","article-title":"Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice","volume":"44","author":"Connolly","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2004.01.005_BIB4","doi-asserted-by":"crossref","unstructured":"Courtney, R., Sansone, A., Statkevich, P., Martinho, M., Laughlin, M. 2003a. Assessment of the pharmacokinetic (PK) and pharmacodynamic (PD) interaction potential between posaconazole and glipizide in healthy volunteers. In: Presented at 2003 Annual Meeting and Exposition of the American Society of Clinical Pharmacology and Therapeutics, April 2\u20135, 2003, Washington, DC, p. PII-63.","DOI":"10.1016\/S0009-9236(03)90524-8"},{"key":"10.1016\/j.ejps.2004.01.005_BIB5","unstructured":"Courtney, R., Sansone, A., Statkevich, P., Martinho, M., Zhang M., Laughlin M., 2003b. Effect of age and gender on the pharmacokinetics of posaconazole in healthy volunteers. In: Presented at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14\u201317, 2003; Chicago, IL, p. A-1563."},{"key":"10.1016\/j.ejps.2004.01.005_BIB6","unstructured":"Courtney, R, Sansone, A., Kantesaria, B., Soni, P., Laughlin, M., 2003c. Effect of ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. In: Presented at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14\u201317, 2003; Chicago, IL, p. A-1564."},{"key":"10.1016\/j.ejps.2004.01.005_BIB7","doi-asserted-by":"crossref","unstructured":"Courtney, R., Wexler D., Radwanski, E., Lim, J., Laughlin, M., 2003d. Effect of food on the relatively bioavailability of 2 oral formulations of posaconazole in healthy adults. Brit. J. Clin. Pharmacol advance online publication. doi: 10.1046\/j.1365-2125.2003.01977.x","DOI":"10.1046\/j.1365-2125.2003.01977.x"},{"key":"10.1016\/j.ejps.2004.01.005_BIB8","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2004.01.005_BIB9","unstructured":"Dannaqui, E., Meletiadis, J., Meis, J.F.G., Mouton, J.W., Verweij, P.E., 2000. In vitro activity of conventional and new antifungals against Zygomycetes. In: Presented at 40th Interscience Conferences on Antimicrobial Agents and Chemotherapy, September 17\u201320, 2000, Toronto, Ont., Canada, p. 370."},{"key":"10.1016\/j.ejps.2004.01.005_BIB10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0009-9236(97)90114-4","article-title":"Validation of the five-drug \u201cPittsburgh cocktail\u201d approach for assessment of selective regulation of drug-metabolizing enzymes","volume":"62","author":"Frye","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2004.01.005_BIB11","doi-asserted-by":"crossref","unstructured":"Gibaldi, M., Perrier, D., 1982. Pharmacokinetics, second ed. Marcel Dekker, New York.","DOI":"10.1201\/b14095"},{"key":"10.1016\/j.ejps.2004.01.005_BIB12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2165\/00003088-199325060-00005","article-title":"Pharmacokinetic drug interactions with antimicrobial agents","volume":"25","author":"Gillum","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2004.01.005_BIB13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1128\/AAC.45.2.633-635.2001","article-title":"In vitro activities of approved and investigational antifungal agents against 44 clinical isolates of basidiomycetous fungi","volume":"45","author":"Gonzalez","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2004.01.005_BIB14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0006-2952(94)90237-2","article-title":"Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily","volume":"48","author":"Gorski","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2004.01.005_BIB15","unstructured":"Hachem, R.Y., Raad, I.I., Afif, C.M., Negroni, R., Graybill, J., Hadley, S., Kantarjian, H., Adams, S., Mukwaya, G., 2000. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections (IFI) refractory (R) to or intolerant (I) to standard therapy (ST). In: Presented at 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17\u201320, 2000, Toronto, Ont., Canada, p. 372."},{"key":"10.1016\/j.ejps.2004.01.005_BIB16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1517\/13543784.9.3.593","article-title":"Novel triazole antifungal agents","volume":"9","author":"Hoffman","year":"2000","journal-title":"Exp. Opin. Invest. Drugs"},{"key":"10.1016\/j.ejps.2004.01.005_BIB17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1128\/AAC.43.3.589","article-title":"Treatment of murine fusariosis with SCH 56592","volume":"43","author":"Lozano-Chiu","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2004.01.005_BIB18","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1128\/AAC.41.7.1558","article-title":"Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis","volume":"41","author":"Lutz","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2004.01.005_BIB19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1365-2354.2001.00241.x","article-title":"Assessing risk factors for systemic fungal infections","volume":"10","author":"Maertens","year":"2001","journal-title":"Eur. J. Cancer Care (Engl.)"},{"key":"10.1016\/j.ejps.2004.01.005_BIB20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/46.2.229","article-title":"A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)","volume":"46","author":"Manavathu","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2004.01.005_BIB21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","article-title":"Update: clinically significant cytochrome P-450 drug interactions","volume":"18","author":"Michalets","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejps.2004.01.005_BIB22","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1128\/AAC.40.8.1910","article-title":"In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans","volume":"40","author":"Perfect","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2004.01.005_BIB23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2004.01.005_BIB24","unstructured":"Sansone, A., Belle, D., Statkevich, P., Joseph D., Kantesaria B., Laughlin, M., Courtney, R., Effect of posaconazole on the pharmacokinetics of tacrolimus in healthy volunteers. In: Presented at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14\u201317, 2003; Chicago, IL, p. A-1603."},{"key":"10.1016\/j.ejps.2004.01.005_BIB25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1067\/mcp.2000.109519","article-title":"Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the \u201cCooperstown cocktail\u201d","volume":"68","author":"Streetman","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2004.01.005_BIB26","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/AAC.40.5.1314","article-title":"In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis","volume":"40","author":"Sugar","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2004.01.005_BIB27","first-page":"557","article-title":"Use of midazolam as a human cytochrome P450 3A probe. Part II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation","volume":"271","author":"Thummel","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2004.01.005_BIB28","first-page":"549","article-title":"Use of midazolam as a human cytochrome P450 3A probe. Part I. In vitro\u2013in vivo correlations in liver transplant patients","volume":"271","author":"Thummel","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2004.01.005_BIB29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/clpt.1990.46","article-title":"Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers","volume":"47","author":"Veronese","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2004.01.005_BIB30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1067\/mcp.2001.119813","article-title":"Assessment of cytochrome P450 activity by a five-drug cocktail approach","volume":"70","author":"Zhu","year":"2001","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098704000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098704000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T02:24:11Z","timestamp":1682648651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098704000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0928098704000211"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2004.01.005","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}